NS-2664

NS-2664 (LS-193,048) is an anxiolytic drug with a novel chemical structure, developed by the small pharmaceutical company NeuroSearch. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. NS-2664 is a potent but non-selective partial agonist at GABAA receptors, although with little efficacy at the α1 subtype and more at α2 and α3. It has potent anticonvulsant effects in animal studies, but a relatively short duration of action, and produces little sedative effects or physical dependence.[1]

NS-2664
Identifiers
IUPAC name
  • 5-furan-3-yl-1-(3-imidazol-1-yl-phenyl)-1H-benzoimidazole
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC20H14N4O
Molar mass326.359 g·mol−1
3D model (JSmol)
SMILES
  • c5occc5-c(cc1nc4)ccc1n4-c2cc(ccc2)-n3cncc3
InChI
  • InChI=1S/C20H14N4O/c1-2-17(23-8-7-21-13-23)11-18(3-1)24-14-22-19-10-15(4-5-20(19)24)16-6-9-25-12-16/h1-14H N
  • Key:QMKRPSVBKKEAKS-UHFFFAOYSA-N N
 NY (what is this?)  (verify)

References
  1. Mirza NR, Nielsen EØ (March 2006). "Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice?". The Journal of Pharmacology and Experimental Therapeutics. 316 (3): 1378–85. doi:10.1124/jpet.105.094474. PMID 16352707. S2CID 22700422.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.